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1. INTRODUCTION {#jmp12396-sec-0005}
===============

In 2017, 10.0 million new cases of tuberculosis (TB) were diagnosed worldwide, with an estimated death of 1.6 million people.[1](#jmp12396-bib-0001){ref-type="ref"} The host immune response plays a critical role in the outcome of *Mycobacterium tuberculosis* (Mtb) infection. Both CD4 and CD8 T cells play important roles in the immunological responses to Mtb through the production of pro‐inflammatory cytokines (IFN‐γ, IL‐2, TNF, and IL‐17), anti‐inflammatory cytokine (IL‐10), and various cytolytic functions[2](#jmp12396-bib-0002){ref-type="ref"}, [3](#jmp12396-bib-0003){ref-type="ref"}, [4](#jmp12396-bib-0004){ref-type="ref"}, [5](#jmp12396-bib-0005){ref-type="ref"}, [6](#jmp12396-bib-0006){ref-type="ref"}, [7](#jmp12396-bib-0007){ref-type="ref"} among other mechanisms. Important roles in the CD4 T cell response to Mtb include production of IFN‐γ as well as production of TNF to optimize macrophage intracellular killing.[8](#jmp12396-bib-0008){ref-type="ref"}, [9](#jmp12396-bib-0009){ref-type="ref"}, [10](#jmp12396-bib-0010){ref-type="ref"} CD4 T cells also stimulate the development of cytolytic CD8 T cell functions important for Mtb killing.[11](#jmp12396-bib-0011){ref-type="ref"}, [12](#jmp12396-bib-0012){ref-type="ref"} Cytolytic CD8 T cells (and CD4 T cells) can produce multiple cytolytic markers (eg granzyme B, granulysin, perforin), which can directly and indirectly kill *Mtb‐*infected macrophages.[13](#jmp12396-bib-0013){ref-type="ref"}, [14](#jmp12396-bib-0014){ref-type="ref"}, [15](#jmp12396-bib-0015){ref-type="ref"} CD8 and CD4 T cells have been studied extensively within the TB literature; however, T cells expressing both CD4 and CD8 (CD4CD8 T cells) have not, leaving a gap in knowledge.

Although CD4 and CD8 T cells account for the majority of the CD3 T cell population, CD4CD8 T cells are present within blood[16](#jmp12396-bib-0016){ref-type="ref"}, [17](#jmp12396-bib-0017){ref-type="ref"}, [18](#jmp12396-bib-0018){ref-type="ref"}, [19](#jmp12396-bib-0019){ref-type="ref"}, [20](#jmp12396-bib-0020){ref-type="ref"} and other sites and play functional roles in a variety of infections.[17](#jmp12396-bib-0017){ref-type="ref"}, [21](#jmp12396-bib-0021){ref-type="ref"}, [22](#jmp12396-bib-0022){ref-type="ref"}, [23](#jmp12396-bib-0023){ref-type="ref"}, [24](#jmp12396-bib-0024){ref-type="ref"}, [25](#jmp12396-bib-0025){ref-type="ref"}, [26](#jmp12396-bib-0026){ref-type="ref"} In humans, approximately 1%‐6% of blood CD3 T cells are CD4CD8 T cells.[16](#jmp12396-bib-0016){ref-type="ref"}, [17](#jmp12396-bib-0017){ref-type="ref"}, [18](#jmp12396-bib-0018){ref-type="ref"}, [19](#jmp12396-bib-0019){ref-type="ref"}, [20](#jmp12396-bib-0020){ref-type="ref"} Despite being low in frequency, CD4CD8 T cells display cytolytic and suppressive functions[16](#jmp12396-bib-0016){ref-type="ref"}, [18](#jmp12396-bib-0018){ref-type="ref"}, [19](#jmp12396-bib-0019){ref-type="ref"}, [27](#jmp12396-bib-0027){ref-type="ref"} (reviewed in[28](#jmp12396-bib-0028){ref-type="ref"}, [29](#jmp12396-bib-0029){ref-type="ref"}). CD4CD8 T cells stimulated with anti‐CD3 or PHA, proliferate and kill target cells through granzyme B, and/or perforin‐dependent[20](#jmp12396-bib-0020){ref-type="ref"}, [27](#jmp12396-bib-0027){ref-type="ref"} and other unspecified mechanisms.[17](#jmp12396-bib-0017){ref-type="ref"} They also express CD107a and produce TNF, IL‐4, IL‐2, IL‐10, IL‐17, and IFN‐γ[20](#jmp12396-bib-0020){ref-type="ref"}, [25](#jmp12396-bib-0025){ref-type="ref"}, [30](#jmp12396-bib-0030){ref-type="ref"} when stimulated with anti‐CD3. CD4CD8 T cells functionally respond to HIV,[17](#jmp12396-bib-0017){ref-type="ref"}, [21](#jmp12396-bib-0021){ref-type="ref"}, [22](#jmp12396-bib-0022){ref-type="ref"} SHIV,[23](#jmp12396-bib-0023){ref-type="ref"} *Mycobacterium leprae,* [24](#jmp12396-bib-0024){ref-type="ref"} and various cancers.[19](#jmp12396-bib-0019){ref-type="ref"}, [20](#jmp12396-bib-0020){ref-type="ref"}, [30](#jmp12396-bib-0030){ref-type="ref"}, [31](#jmp12396-bib-0031){ref-type="ref"} CD4CD8 T cells from adults with rheumatoid arthritis produce more IFN‐γ than peripheral CD4 and CD8 T cells stimulated with mitogens.[32](#jmp12396-bib-0032){ref-type="ref"} Taken together, CD4CD8 T cells express both pro‐inflammatory and anti‐inflammatory cytokines production and are able to exhibit cytolytic function. However, they have not been examined in the context of TB.

Here, we sought to characterize these CD4CD8 T cells during the course of Mtb infection in the blood, airways, and lung granulomas using a cynomolgus macaque model of TB. We show that CD4CD8 T cells increase in frequency in both blood and the airways during early Mtb infection and within lung granulomas with Mtb‐specific responses that are similar but distinct in pattern from conventional single‐expressing CD4 and CD8 T cells.

2. METHODS {#jmp12396-sec-0006}
==========

2.1. Animals {#jmp12396-sec-0007}
------------

Adult (\>4 years of age) cynomolgus macaques (*Macaca fascicularis*) were screened for other co‐morbidities (eg parasites, SIV) before infection (Valley Biosystems, Sacramento, CA). Animals were infected with low‐dose (\~25 CFU per monkey) Mtb (Erdman strain) via bronchoscopic instillation to the lower lung lobe and housed in Biosafety Level 3 (BSL‐3) primate facility.[2](#jmp12396-bib-0002){ref-type="ref"}, [33](#jmp12396-bib-0033){ref-type="ref"}, [34](#jmp12396-bib-0034){ref-type="ref"} Infection was confirmed as previously described.[34](#jmp12396-bib-0034){ref-type="ref"} Animals were declared as having active disease (ie repeated presence of Mtb growth in bronchoalveolar lavage \[BAL\] or gastric aspirate, elevated sedimentation rate \[ESR\], and/or clinical signs of active TB after infection) or latent infection (ie no clinical signs of active TB, normal ESR, and lack of persistent Mtb growth by 6 months post‐infection) based on previously published criteria.[34](#jmp12396-bib-0034){ref-type="ref"} Twenty‐four monkeys were included in the PBMC intracellular cytokine (ICS) analysis, 28 monkeys were included in the BAL profile, and eight monkeys were included in the lung granuloma profile. Due to restrictions on animal procedures or low cell counts, some time points use fewer monkeys. Immune data for eight of these animals were previously published[2](#jmp12396-bib-0002){ref-type="ref"}, [35](#jmp12396-bib-0035){ref-type="ref"} but without CD4CD8 T cell analysis. All animal protocols and procedures were approved by the University of Pittsburgh\'s Institutional Animal Care and Use Committee that adheres to the national guidelines established in the Animal Welfare Act and Guide for the Care and Use of Laboratory Animals as mandated by the U. S. Public Health Service Policy.

2.2. Procedures {#jmp12396-sec-0008}
---------------

Cells from the BAL and PBMCs were obtained for analysis prior to Mtb infection, 4 weeks, 12 weeks post‐infection, and at time of clinical diagnosis (latent or active TB) as previously described.[36](#jmp12396-bib-0036){ref-type="ref"}, [37](#jmp12396-bib-0037){ref-type="ref"} Isolated cells were stimulated with ESAT6‐CFP10 peptide pools (10 μg/mL of every peptide) or incubated with only media (RPMI+10%hAB). PBMC incubated with or without the peptide pools for 1 hour in media, followed by the addition of Brefeldin A (Golgiplug: BD biosciences) for 5 hours at 37°C with 5% CO~2~. ESAT6‐CFP10 responses within PBMC T cells are presented after subtracting responses from PBMC incubated with media. BAL and granuloma cells were isolated and stimulated for 4 hours with peptide pools in the presence of Brefeldin A. When used, CD107a antibody was added prior to incubation. A minimum of 5 × 10^5^ BAL or PBMC cells were incubated with each stimulation condition and acquired.

A total of 29 granulomas were used for analysis from eight macaques (2‐5 granulomas per animal) using the same ICS protocol as above for BAL. The range of cells analyzed from granulomas included CD4 (median = 116, IQR~25%‐75%~ = 80‐347), CD8 (median = 135, IQR~25%‐75%~ = 78‐304), and CD4CD8 (median = 111, IQR~25%‐75%~ = 74‐260). T cells were in the estimated range of a previously published threshold.[2](#jmp12396-bib-0002){ref-type="ref"} Granuloma‐specific T cell responses were only available from clinically latent animals as animals with active TB were dedicated for other studies and immune data were not available.

2.3. Flow cytometry {#jmp12396-sec-0009}
-------------------

Flow cytometry was performed on PBMC, BAL, and granuloma cells after stimulation and stained with a combination of antibodies (Table [S1](#jmp12399-sup-0003){ref-type="supplementary-material"}), as previously described.[2](#jmp12396-bib-0002){ref-type="ref"}, [12](#jmp12396-bib-0012){ref-type="ref"} PBMC were stained for 2 panels: cytokines (CD3, CD4, CD8, IFN‐γ, TNF, IL‐2, IL‐10, and IL‐17) or cytolytic markers (CD107a, granzyme B, granulysin, perforin). BAL cells were stained for CD3, CD4, CD8, IFN‐γ, TNF, IL‐2, IL‐10, and IL‐17. Granuloma cells were stained for CD3, CD4, CD8, IFN‐γ, TNF, IL‐2, IL‐10, IL‐17, and granzyme B. Data acquisition was performed using an LSR II (BD) and analyzed using FlowJo Software v.9.7 (Treestar Inc, Ashland, OR). Gating strategies used for analysis are presented using ESAT6‐CFP10‐stimulated PBMC (Figure [S1](#jmp12399-sup-0001){ref-type="supplementary-material"}). To eliminate the possibility that CD4CD8 T cell population is a result of fluorophore spillover, the population was confirmed using combinations of fluorophores that are excited by different lasers (Figure [S1](#jmp12399-sup-0001){ref-type="supplementary-material"}).

2.4. Statistical analysis {#jmp12396-sec-0010}
-------------------------

Data were tested for normality with the Shapiro‐Wilk test and were not consistently normally distributed, so all statistics utilized were non‐parametric analyses (JMP Pro 12.1.0 statistical software). Kruskal‐Wallis test with Dunn\'s multiple comparison test was used to compare changes in cell type, cytokine production, and cytolytic marker expression over time within BAL and PBMC (GraphPad Prism 7.0d statistical software). Wilcoxon method (with unadjusted *P*‐values) was used to compare frequencies of CD4, CD8, and CD4CD8 T cells in PBMC and BAL and granulomas within the same time points (JMP Pro 12.1.0 statistical software). Statistical significance was set at *P* ≤ 0.05. All *P* values *P* ≤ 0.1 are displayed to represent statistical trends.

3. RESULTS {#jmp12396-sec-0011}
==========

To characterize the dynamics in CD4CD8 T cells during the course of Mtb infection, the frequency and function of CD4CD8 T cells in PBMC and BAL were examined before *M. tuberculosis* infection, 4 weeks, 12 weeks post‐infection, and at the time of latent infection diagnosis (at 6 months after infection) and active TB diagnosis (typically before 6 months after infection) (Figure [1](#jmp12396-fig-0001){ref-type="fig"}). CD4CD8 T cell frequencies doubled from pre‐infection levels at 4 weeks post‐Mtb infection (Figure [1](#jmp12396-fig-0001){ref-type="fig"}) in both PBMC and BAL cells. At 4 weeks post‐Mtb infection, an increased production of Mtb‐specific TNF and granzyme B was observed in PBMC CD4CD8 T cells compared to pre‐infection levels (Figure [1](#jmp12396-fig-0001){ref-type="fig"}). Similarly, CD4CD8 T cells in the airways increased significantly at 4 weeks post‐Mtb infection compared to pre‐infection levels. Higher frequencies of TNF producing airway CD4CD8 T cells were also seen at 4 weeks after Mtb infection but then decreased to pre‐infection levels during the remaining infection period.

![Frequency and function of CD4CD8 T cells in PBMC and BAL during macaque *Mycobacterium tuberculosis (Mtb)* infection. A, Increased frequencies of CD4CD8 T cells in PBMCs are seen at 4 wks after infection (from baseline) with an increase in Mtb‐specific production of TNF and granzyme B observed among CD4CD8 T cells. Cytokine production in ESAT6‐CFP10‐stimulated PBMC was subtracted from cytokine production by PBMC incubated with media. (B) An increased frequency of CD4CD8 T cells from bronchoalveolar lavage (BAL) is observed soon after Mtb infection with increased Mtb‐specific TNF production. Samples were obtained before infection ("Pre"), at 4 ("4 wk") and 12 ("12 wk") weeks after Mtb infection, and at the time in which animals met the clinical definition of active or latent infection ("Dx"). Twenty‐four and 28 monkeys were included in the PBMC and BAL analyses, respectively. Kruskal‐Wallis tests with Dunn\'s multiple comparison post test were used to determine significance with *P*‐values as indicated](JMP-48-82-g001){#jmp12396-fig-0001}

To distinguish PBMC and BAL CD4CD8 T cells from CD4 or CD8 T cells, we compared the frequency and activity of each cell type within the same time point during infection (Tables [1](#jmp12396-tbl-0001){ref-type="table"} and [2](#jmp12396-tbl-0002){ref-type="table"}). In blood, a significantly smaller frequency of CD4CD8 T cells was observed at all time points compared to CD4 and CD8 T cells. Within PBMC, CD4CD8 T cells are able to produce both cytolytic markers and Th1 cytokines during acute TB. At 4 weeks post‐Mtb infection, Mtb‐specific CD4CD8 T cells in PBMC express a trend of higher CD107a than CD4 T cells, and significantly more granzyme B and perforin than CD4 T cells (Table [1](#jmp12396-tbl-0001){ref-type="table"}) but not CD8 T cells. In contrast, a higher proportion of perpiheral CD4CD8 T cells producing Mtb‐specific IFN‐γ and TNF were observed at 4 weeks after infection compared to CD8 T cells (Table [1](#jmp12396-tbl-0001){ref-type="table"}). Taken together, peripheral CD4CD8 T cells appear to have higher cytolytic potential during acute Mtb infection than CD4 T cells but more Mtb‐specific cytokine producing properties than CD8 T cells.

###### 

Frequency of T cells from peripheral blood mononuclear cells (PBMC) producing antigen‐specific cytokines during *Mycobacterium tuberculosis* infection in non‐human primates (n = 28)

  PBMC           Weeks post‐Mtb infection   CD4                  CD4CD8               CD8                  *P* value (CD4 vs CD4CD8)   *P* value (CD8 vs CD4CD8)
  -------------- -------------------------- -------------------- -------------------- -------------------- --------------------------- ---------------------------
  T cell %       0                          52.9 \[40.0‐58.4\]   2.2 \[0.77‐4.4\]     35.6 \[30.1‐41.6\]   \<0.0001                    \<0.0001
  4 wk           46.7 \[36.6‐54.9\]         4.4 \[3.1‐7.5\]      40.0 \[31.9‐47.0\]   \<0.0001             \<0.0001                    
  12 wk          45.4 \[36.5‐54.3\]         3.8 \[0.80‐5.9\]     43.3 \[34.3‐51.5\]   \<0.0001             \<0.0001                    
  Dx             52.5 \[40.0‐58.8\]         3.9 \[1.2‐8.1\]      38.3 \[31.1‐45.8\]   \<0.0001             \<0.0001                    
  CD107a %       0                          0.05 \[0‐0.2\]       0.081 \[0‐0.50\]     0.1 \[0.02‐0.42\]                                
  4 wk           0.015 \[0‐0.56\]           0.1 \[0‐0.43\]       0.25 \[0.07‐0.42\]   0.0570                                           
  12 wk          0.028 \[0‐0.10\]           0.10 \[0‐0.20\]      0.11 \[0.01‐0.44\]                                                    
  Dx             0 \[0‐0.12\]               0.19 \[0‐1.3\]       0 \[0‐0.2\]          0.0722                                           
  Granulysin %   0                          0.08 \[0‐0.45\]      0.4 \[0‐1.5\]        0.4 \[0.04‐1.6\]                                 
  4 wk           0.2 \[0‐0.56\]             0.7 \[0‐1.9\]        0.9 \[0.3‐1.3\]                                                       
  12 wk          0.1 \[0‐0.42\]             0.3 \[0‐0.56\]       0.4 \[0‐1.0\]                                                         
  Dx             0.067 \[0‐1.1\]            0 \[0‐1.4\]          0.065 \[0‐3.2\]                                                       
  Granzyme B %   0                          0.14 \[0‐1.4\]       0.49 \[0‐4.6\]       0.24 \[0‐3.5\]                                   
  4 wk           0.8 \[0.1‐2.9\]            5.2 \[0.9‐13.9\]     2.1 \[0.2‐15.2\]     0.0207                                           
  12 wk          3.0 \[0.03‐5.2\]           3.4 \[0‐12.7\]       1.4 \[0‐18.1\]                                                        
  Dx             0 \[0‐4.0\]                0 \[0‐4.5\]          0.3 \[0‐4.01\]                                                        
  Perforin %     0                          0 \[0‐0.05\]         0.19 \[0‐0.97\]      0.3 \[0.01‐1.4\]     0.0288                      
  4 wk           0.06 \[0.02‐0.45\]         1.04 \[0.5‐2.1\]     0.69 \[0.3‐2.4\]     0.0434                                           
  12 wk          0.02 \[0‐0.09\]            0.1 \[0‐0.42\]       0.23 \[0.1‐0.51\]                                                     
  Dx             0 \[0‐0.2\]                0 \[0‐0.47\]         0.023 \[0‐0.83\]                                                      
  IL10%          0                          0.01 \[0‐0.2\]       0.40 \[0‐1.3\]       0.01 \[0‐0.1\]                                   
  4 wk           0.7 \[0‐3.5\]              0 \[0‐0.9\]          0 \[0‐0.5\]                                                           
  12 wk          0.012 \[0‐3.5\]            0 \[0‐0.8\]          0.11 \[0‐0.3\]                                                        
  Dx             0.52 \[0‐1.3\]             0.29 \[0.01‐1.6\]    0.53 \[0‐4.4\]                                                        
  IFN‐γ %        0                          0.03 \[0‐0.13\]      0 \[0‐0.72\]         0.03 \[0‐0.14\]                                  
  4 wk           0.15 \[0.02‐0.34\]         0.25 \[0‐0.75\]      0.05 \[0‐0.16\]                           0.0401                      
  12 wk          0.10 \[0.03‐0.30\]         0.07 \[0‐0.40\]      0.06 \[0.01‐0.14\]                                                    
  Dx             0.02 \[0‐1.3\]             0.07 \[0‐5.0\]       0 \[0‐1.4\]                                                           
  IL2%           0                          0.093 \[0‐0.15\]     0.27 \[0‐0.53\]      0.11 \[0.02‐0.20\]                               
  4 wk           0.13 \[0.04‐0.32\]         0.002 \[0‐1.5\]      0.11 \[0.02‐0.36\]                                                    
  12 wk          0.09 \[0.04‐0.34\]         0.42 \[0‐0.76\]      0.083 \[0‐0.27\]                                                      
  Dx             1.2 \[0.2‐2.9\]            0 \[0‐0.01\]         0.1 \[0‐3.7\]        \<0.0001             0.0011                      
  TNF %          0                          0.045 \[0‐0.12\]     0.015 \[0‐0.18\]     0.037 \[0‐0.08\]                                 
  4 wk           0.36 \[0.06‐0.47\]         0.49 \[0.11‐1.04\]   0.12 \[0‐0.33\]                           0.0196                      
  12 wk          0.20 \[0.01‐0.40\]         0.33 \[0‐1.1\]       0.16 \[0.02‐0.3\]                                                     
  Dx             0.47 \[0.02‐1.2\]          0.41 \[0‐1.7\]       0 \[0‐0.84\]                              0.0998                      
  IL17%          0                          0 \[0‐0.08\]         0 \[0‐0\]            0 \[0‐0.17\]                                     
  4 wk           0.10 \[0‐0.76\]            0.13 \[0‐1.6\]       0.015 \[0‐0.24\]                                                      
  12 wk          0.014 \[0‐0.22\]           0.03 \[0‐0.58\]      0.0043 \[0‐0.2\]                                                      
  Dx             0.76 \[0.15‐2.8\]          1 \[0‐3.5\]          0.018 \[0‐1.9\]                                                       

CD4, CD4CD8, and CD8 T cells within the T cell gate (CD3+) are shown in the top row. Percentages of cells expressing each cytolytic marker or cytokine are represented for CD4, CD4CD8, or CD8 T cells. ESAT6/CFP10 stimulated cells were subtracted from media incubated cells. Analysis performed across each cell type within each time point using the (unadjusted *P*‐values shown in last column).

Dx, time that clinical outcome is declared (active disease or latent infection); Wk, weeks post‐infection.

Significance is *P* ≤ 0.05.

John Wiley & Sons, Ltd

###### 

Frequency of T cells from bronchoalveolar lavage cells producing cytokines during *Mycobacterium tuberculosis* infection in non‐human primates (n = 28). CD4, CD4CD8, and CD8 T cells within the T cell gate (CD3+) are shown in the top row

  BAL        Weeks post‐Mtb infection   CD4                  CD4CD8               CD8                  *P* value (CD4 vs CD4CD8)   *P* value (CD8 vs CD4CD8)
  ---------- -------------------------- -------------------- -------------------- -------------------- --------------------------- ---------------------------
  T cell %   0                          36.8 \[31.4‐45.6\]   4.0 \[2.5‐6.2\]      39.7 \[31.3‐46.1\]   \<0.0001                    \<0.0001
  4 wk       30.5 \[22.4‐42.0^\]^       8.0 \[4.1‐15.3\]     42 \[40.5‐49.6\]     \<0.0001             \<0.0001                    
  12 wk      37.4 \[23.0‐45.2\]         3.9 \[2.5‐12.6\]     44.6 \[39.9‐52.5\]   \<0.0001             \<0.0001                    
  Dx         33.4 \[26.6‐44.3\]         2.9 \[1.2‐9.2\]      50.2 \[40.8‐56.6\]   \<0.0001             \<0.0001                    
  IFN‐γ %    0                          0.75 \[0.4‐2.2\]     6.5 \[0.6‐16.0\]     2.1 \[0.7‐5.5\]      0.0027                      0.0232
  4 wk       2.9 \[1.1‐9.4\]            5.3 \[2.8‐9.6\]      1.4 \[0.5‐2.5\]      0.0753               \<0.0001                    
  12 wk      2.9 \[0.98‐6.3\]           3.4 \[1.4‐5.6\]      0.85 \[0.5‐2.2\]                          0.0001                      
  Dx         1.45 \[0.5‐4.1\]           1.2 \[0.3‐2.8\]      0.3 \[0.1‐0.6\]                           0.0126                      
  IL‐10%     0                          2.3 \[0.9‐7.3\]      8.1 \[3.3‐13.6\]     2.5 \[1.1‐3.7\]      0.0192                      0.0020
  4 wk       1 \[0.2‐3.7\]              6.1 \[2.2‐13.2\]     1.1 \[0.38‐4.3\]     0.0284               0.0365                      
  12 wk      1.9 \[0.6‐5.4\]            9.7 \[4.9‐19.2\]     2.4 \[0.5‐13.6\]     0.0015                                           
  Dx         0.66 \[0.2‐3.2\]           7.1 \[0‐13.6\]       1.7 \[0.05‐6.5\]                                                      
  IL‐17%     0                          1.4 \[0.7‐3.1\]      5.6 \[2.6‐14.6\]     1.25 \[0.6‐2.6\]     \<0.0001                    \<0.0001
  4 wk       2.4 \[1.2‐7.9\]            5.3 \[2.4‐10.4\]     0.95 \[0.5‐3.7\]     0.0464               0.0016                      
  12 wk      0.8 \[0.3‐2.6\]            2.8 \[1.6‐7.7\]      0.3 \[0.1‐0.58\]     0.0008               \<0.0001                    
  Dx         0.34 \[0‐1.9\]             4.76 \[1.7‐9.9\]     0.35 \[0.1‐0.65\]    \<0.0001             \<0.0001                    
  IL‐2%      0                          1.3 \[0.8‐5.5\]      5.1 \[2.3‐9.6\]      1.3 \[0.8‐2.6\]      0.0046                      0.0001
  4 wk       3.6 \[1.5‐5.2\]            4.7 \[3.3‐7.0\]      1.6 \[0.9‐2.1\]                           0.0003                      
  12 wk      2.3 \[1.4‐3.4\]            3.4 \[2.4‐5.1\]      0.8 \[0.5‐1.7\]      0.0460               \<0.0001                    
  Dx         2.1 \[1.0‐3.2\]            2.4 \[0.9‐5.8\]      1.1 \[0.2‐1.7\]                           0.0236                      
  TNF %      0                          1.5 \[0.9‐4\]        6.5 \[1.6‐10.7\]     2.8 \[1.5‐7.8\]      \<0.0051                    
  4 wk       6.8 \[3‐12.3\]             10.0 \[4.1‐19.4\]    2.6 \[0.9‐9.2\]                           0.0018                      
  12 wk      5.1 \[2.5‐8.1\]            5.2 \[3.2‐7.4\]      2 \[1.0‐3.0\]                             0.0001                      
  Dx         1.8 \[0.2‐5.2\]            0.76 \[0.4‐5.3\]     1.2 \[0.2‐3.2\]                                                       

Percentages of cells expressing each cytokine are represented for CD4, CD4CD8, or CD8 T cells from cells stimulated with ESAT6/CFP10. Analysis performed on each pair of cell types at each time point using the Wilcoxon method (unadjusted *P*‐values shown in last column).

Dx, time that clinical outcome is declared (active disease or latent infection); Wk, weeks post‐infection.

Significance is *P* ≤ 0.05.

John Wiley & Sons, Ltd

Similar to blood, the frequency of CD4CD8 T cells in the airway was significantly lower compared to CD4 and CD8 T cells. In contrast to blood, airway CD4CD8 T cells expressed significantly greater IFN‐γ, IL‐10, IL‐17, IL‐2, and TNF than CD4 and CD8 T cells prior to Mtb infection suggesting that these cells may play a non‐specific role but could contribute to the immune response in the airways. At 4 weeks post‐Mtb infection, CD4CD8 T cells produced more IL‐17 and IL‐10 compared to both CD4 and CD8 T cell and greater Th1 cytokines (IFN‐γ, TNF, and IL‐2) than CD8 T cells (Table [2](#jmp12396-tbl-0002){ref-type="table"}). Over the duration of the infection, CD4CD8 T cells were more likely to produce more IFN‐γ and IL‐2 than CD8 T cells. Interestingly, IL‐17 production within CD4CD8 T cells was higher than both CD4 and CD8 T cells. At the time of diagnoses, macaques that developed active TB maintained a lower frequency of BAL CD4CD8 T cells compared to those with controlled latent Mtb infection (Figure [S2](#jmp12399-sup-0002){ref-type="supplementary-material"}) though no differences in cytokine production were observed. These data suggest that CD4CD8 T cells have overlapping functions with both CD4 and CD8 T cells, but that their function in the airway compartment may be quite different than the blood.

Lung granulomas, a collection of localized immune cells (eg lymphocytes, macrophages, neutrophils), are the hallmark of Mtb infection and play a critical role in direct pathogen‐host interaction. T cell responses in the granuloma are known to play a key role in outcome; therefore, we sought to characterize the frequency and functionality of CD4CD8 T cells in granulomas (Figure [2](#jmp12396-fig-0002){ref-type="fig"}) and compare them to single positive CD4 and CD8 T cells. CD4CD8 T cell accounted for a median of 11% of CD3 T cells in the granuloma, and this was significantly less than the 36.2% CD4 T cells and 25% CD8 T cells (Figure [2](#jmp12396-fig-0002){ref-type="fig"}A). A significantly lower frequency of CD4CD8 T cells expressed granzyme B compared to both CD4 and CD8 T cells (Figure [2](#jmp12396-fig-0002){ref-type="fig"}A). The proportion of CD4CD8 T cells producing IL‐10 was greater than CD8 T cells but similar to CD4 T cells. In contrast, the proportion of TNF producing CD4CD8 T cells was significantly higher than CD4 T cells and more similar to CD8 T cells. No differences were observed in their production of IFN‐γ, IL‐2, or IL‐17 compared to conventional CD4 and CD8 T These data demonstrate that CD4CD8 T cells have both distinct and similar functions from CD4 and CD8 T cells within individual granulomas.

![CD4CD8 T cells are distinct from CD4 and CD8 T cells in both frequency and function within lung granulomas of *M. tuberculosis‐*infected macaques. A) CD4CD8 T cells are lower in frequency than CD4 and CD8 T cells. B) CD4CD8 T cells produce less granzyme B than CD4 and CD8 T cells. C and D) Differences in TNF and IL‐10 production in CD4CD8 T cells compared to CD4 and CD8 T cells. Each data point represents an individual lung granulomas. Different symbols represent individual macaques. Kruskal‐Wallis test with Dunn\'s multiple comparison (post hoc), *P*‐values shown](JMP-48-82-g002){#jmp12396-fig-0002}

In summary, CD4CD8 T cells are increased in frequency during early Mtb infection in the blood and airways and can be found in granulomas with distinct Mtb‐specific functions from single‐expressing CD4 and CD8 T cells.

4. DISCUSSION {#jmp12396-sec-0012}
=============

This study aimed to characterize the frequency and function of CD4CD8 T cells during Mtb infection in PBMC, BAL, and lung granulomas and determine if they are functionally distinct from CD4 and CD8 T cells. CD4CD8 T cells are traditionally regarded as existing during a time of cellular differentiation toward CD4 or CD8 T cells. However, extrathymic CD4CD8 T cells located within the blood and numerous tissues have been reported[27](#jmp12396-bib-0027){ref-type="ref"}, [28](#jmp12396-bib-0028){ref-type="ref"}, [32](#jmp12396-bib-0032){ref-type="ref"}, [38](#jmp12396-bib-0038){ref-type="ref"}, [39](#jmp12396-bib-0039){ref-type="ref"} and more than 96% of blood CD4CD8 T cells express alpha‐beta TCR.[32](#jmp12396-bib-0032){ref-type="ref"}

We determined that CD4CD8 T cells represent a minority population of T cells within PBMC (median ranges pre‐ and 4 week post‐infection of 2.2%‐4.4%), BAL (median ranges pre‐ and 4 weeks post‐infection of 2.9%‐8.0%), and lung granulomas (median 11%). In blood, Mtb‐specific CD4CD8 T cells express more cytolytic markers (CD107a, granzyme B, and perforin) than CD4 T cells but not CD8 T cells and more Th1 cytokines (TNF and IFN‐γ) than CD8 T cells that was most robust at 4 weeks after Mtb infection compared to baseline. The pattern of greater cytolytic function among CD4CD8 T cells is consistent with reports from others.[27](#jmp12396-bib-0027){ref-type="ref"} The early increase in TNF production is consistent with the acute peripheral CD4 and CD8 T cell cytokine responses during this period and was associated with animals that developed active TB compared to latent infection suggesting that the responses were likely associated with TB pathology. While their proportions were small, CD4CD8 T cells in the BAL produced Th1 (IFN‐γ and IL‐2) and Th17 (IL‐17) cytokines more robustly than either the CD8 or CD4 T cells before and during the course of infection. There was a significant increase in the frequency of CD4CD8 T cells at 4 weeks post‐Mtb infection with greater production of Th1 cytokines than CD8 T cells. At this time point, CD4CD8 T cells also produced more IL‐10 than mono‐expressing CD4 or CD8 T cells. Taken together, these data suggest that these cells have both pro‐inflammatory (Th1) and anti‐inflammatory (IL‐10) roles that are important in the immune response to Mtb infection.

Within the granuloma, CD4CD8 T cells were present in higher frequencies than BAL and PBMC. CD4CD8 T cells express more IL10 than CD8 T cells (similar to the BAL cells) and TNF than CD4 T cells and produce similar amounts of IFN‐γ, IL2, IL17, and IL4 as CD4 and CD8 T cells. The transient increase in frequency of CD4CD8 T cells in both PBMC and BAL during early Mtb infection and the observed higher frequency of CD4CD8 T cells in the granuloma would suggest that these cells are being recruited during early infection and transiting the blood and airways to the granuloma, where the host‐pathogen response is most critical.

In conclusion, we have identified a small population of T cells that express both CD4 and CD8 receptors that have both cytokine and cytotoxic capacities. Their responses during Mtb infection are similar in property but different in characteristic than mono‐expressing CD4 or CD8 T cells. Furthermore, their role in the host immune response is likely dependent on their inherent immunologic compartments (eg blood vs airway vs granulomas), whose characteristics differ during the course of Mtb infection. Even within an individual anatomic compartment, these cells are heterogeneous and able to produce both pro‐inflammatory (Th1 and Th17 driven response) and anti‐inflammatory (IL‐10) cytokines that are important to the balance of host immune responses in tuberculosis. Further characterization of their activation and suppression signals would be of interest for future studies. Importantly, this dual expressing T cell population is often combined with either CD4 or CD8 T cells populations but as we have shown, their function is different from mono‐expression CD4 or CD8 T cells. Therefore, we recommend that CD4CD8 T cells should be separately analyzed from single‐expressing CD4 and CD8 T cells in immunologic studies.
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